Adoptive cancer immunotherapy utilizing lymphokine activated killer cells and gamma interferon activated killer monocytes
- 31 December 1988
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 38 (3) , 453-465
- https://doi.org/10.1016/0163-7258(88)90014-9
Abstract
No abstract availableThis publication has 53 references indexed in Scilit:
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating LymphocytesScience, 1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Tumor Necrosis Factor (TNF)Science, 1985
- Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancerCancer, 1985
- Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2Science, 1984
- Site-Specific Mutagenesis of the Human Interleukin-2 Gene: Structure-Function Analysis of the Cysteine ResiduesScience, 1984
- Interferon-γ is required in activation of macrophages for tumor cytotoxicityCellular Immunology, 1983
- Tumor cell killing by freshly isolated peripheral blood monocytesCellular Immunology, 1981
- Selective in Vitro Growth of T Lymphocytes from Normal Human Bone MarrowsScience, 1976